Not checkedNot checked for notices yet.
Alternative splicing in endothelial cells: novel therapeutic opportunities in cancer angiogenesis
Anna Di Matteo, Elisa Belloni, Davide Pradella and 4 more
Journal of Experimental & Clinical Cancer Research · 2020
doi:10.1186/s13046-020-01753-1 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Abstract Alternative splicing (AS) is a pervasive molecular process generating multiple protein isoforms, from a single gene. It plays fundamental roles during development, differentiation and maintenance of tissue homeostasis, while aberrant AS is considered a hallmark of multiple diseases, including cancer. Cancer-restricted AS isoforms represent either predictive biomarkers for diagnosis/prognosis or targets for anti-cancer therapies. Here, we discuss the contribution of AS regulation in cancer angiogenesis, a complex process supporting disease development and progression. We consider AS programs acting in a specific and non-redundant manner to influence morphological and functional changes involved in cancer angiogenesis. In particular, we describe relevant AS variants or splicing regulators controlling either secreted or membrane-bound angiogenic factors, which may represent attractive targets for therapeutic interventions in human cancer.
Abstract licence: CC BY
References217
40 more references, whose wording the paper’s licence keeps private.
All 217 referencesReads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.